Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Jocelyn Bosse, Alessandro Cerri, Oliver Fairhurst and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Anastasiia Kyrylenko (Book Review Editor).

InternKats: Simone Lorenzi and Asude Sena Moya.
COPA v Wright: Civil Restraint Orders and Vexatious Litigation COPA v Wright: Civil Restraint Orders and Vexatious Litigation Reviewed by Oliver Fairhurst on Thursday, May 22, 2025 Rating: 5
[Guest post] Third-party registration of well-known foreign trade marks in the EU: The Frisby case [Guest post] Third-party registration of well-known foreign trade marks in the EU: The Frisby case Reviewed by Eleonora Rosati on Thursday, May 22, 2025 Rating: 5
Never Too Late: If you missed the IPKat last week! Never Too Late: If you missed the IPKat last week! Reviewed by Simone Lorenzi on Wednesday, May 21, 2025 Rating: 5
[Guest post] Nigeria’s Copyright Collective Management Regulations: Justice for Members Only? [Guest post] Nigeria’s Copyright Collective Management Regulations: Justice for Members Only? Reviewed by Anastasiia Kyrylenko on Tuesday, May 20, 2025 Rating: 5
Glaxo’s colour trade mark for inhalers invalidated Glaxo’s colour trade mark for inhalers invalidated Reviewed by Marcel Pemsel on Tuesday, May 20, 2025 Rating: 5
An LLM is not (yet) a person skilled in the art (T 1193/23) An LLM is not (yet) a person skilled in the art (T 1193/23) Reviewed by Dr Rose Hughes on Monday, May 19, 2025 Rating: 5
First UPC decision to tackle infringement and validity of second medical claims (Sanofi v Amgen, UPC_CFI_505/2024) First UPC decision to tackle infringement and validity of second medical claims (Sanofi v Amgen, UPC_CFI_505/2024) Reviewed by Dr Rose Hughes on Monday, May 19, 2025 Rating: 5
[Guest Post] Exhaustion of Trade Mark Rights and the Burden of Proof: Coty/Easycosmetic [Guest Post] Exhaustion of Trade Mark Rights and the Burden of Proof: Coty/Easycosmetic Reviewed by Marcel Pemsel on Friday, May 16, 2025 Rating: 5
Government announces that UK+ IP exhaustion regime is here to stay Government announces that UK+ IP exhaustion regime is here to stay Reviewed by Jocelyn Bosse on Thursday, May 15, 2025 Rating: 5
Never Too Late: If you missed the IPKat last week! Never Too Late: If you missed the IPKat last week! Reviewed by Asude Sena Moya on Wednesday, May 14, 2025 Rating: 5
Defining the undefinable: The challenges and opportunities for cell therapy IP Defining the undefinable: The challenges and opportunities for cell therapy IP Reviewed by Dr Rose Hughes on Tuesday, May 13, 2025 Rating: 5
AI and Copyright - the Kidron Amendments AI and Copyright - the Kidron Amendments Reviewed by Oliver Fairhurst on Tuesday, May 13, 2025 Rating: 5
The never-ending story of Brexit – Chapter: EUIPO v Nowhere – Act I: The Advocate General’s Opinion The never-ending story of Brexit – Chapter: EUIPO v Nowhere – Act I: The Advocate General’s Opinion Reviewed by Marcel Pemsel on Tuesday, May 13, 2025 Rating: 5
[Guest Post] A shotgun revocation? Did the South African court jump the gun in Regents of the University of California v Eurolab & Dis-Chem? [Guest Post] A shotgun revocation? Did the South African court jump the gun in Regents of the University of California v Eurolab & Dis-Chem? Reviewed by Simone Lorenzi on Monday, May 12, 2025 Rating: 5
[Guest Post] Out the Door, Back In Through the Grille: Warsaw Court Reverses Audi Advantage [Guest Post] Out the Door, Back In Through the Grille: Warsaw Court Reverses Audi Advantage Reviewed by Marcel Pemsel on Sunday, May 11, 2025 Rating: 5
UK court reaffirms its stringent plausibility standard in AstraZeneca despite G 2/21 UK court reaffirms its stringent plausibility standard in AstraZeneca despite G 2/21 Reviewed by Annsley Merelle Ward on Friday, May 09, 2025 Rating: 5
Commercial success is a nothing-burger for the EPO in Wegovy patent inventive step analysis (T 1701/22, Obesity treatment with semaglutide) Commercial success is a nothing-burger for the EPO in Wegovy patent inventive step analysis (T 1701/22, Obesity treatment with semaglutide) Reviewed by Dr Rose Hughes on Thursday, May 08, 2025 Rating: 5
Subscribe to: Posts ( Atom )
Powered by Blogger.